Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate
Autore:
Deeks, SG; Barditch-Crovo, P; Collier, A; Smith, A; Miller, M; McGowan, M; Coakley, DF;
Indirizzi:
Univ Calif San Francisco, San Francisco Gen Hosp, AIDS Program, San Francisco, CA 94110 USA Univ Calif San Francisco San Francisco CA USA 94110 ancisco, CA 94110 USA Johns Hopkins Univ, Sch Med, Baltimore, MD 21231 USA Johns Hopkins Univ Baltimore MD USA 21231 ch Med, Baltimore, MD 21231 USA Univ Washington, Sch Med, Seattle, WA 98195 USA Univ Washington Seattle WA USA 98195 gton, Sch Med, Seattle, WA 98195 USA Gilead Sci Inc, Foster City, CA USA Gilead Sci Inc Foster City CA USAGilead Sci Inc, Foster City, CA USA
Titolo Testata:
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
fascicolo: 4, volume: 28, anno: 2001,
pagine: 336 - 339
SICI:
1525-4135(200112)28:4<336:HDNETA>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; DIDANOSINE; SAFETY;
Keywords:
HIV-1; tenofovir; antiretroviral therapy; hydroxyurea;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
7
Recensione:
Indirizzi per estratti:
Indirizzo: Deeks, SG Univ Calif San Francisco, San Francisco Gen Hosp, AIDS Program, 995 Potrero Ave, San Francisco, CA 94110 USA Univ Calif San Francisco 995 Potrero Ave San Francisco CA USA 94110
Citazione:
S.G. Deeks et al., "Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate", J ACQ IMM D, 28(4), 2001, pp. 336-339

Abstract

Tenofovir disoproxil fumarate (DF) is an adenosine analogue with significant activity against HIV-1. Hydroxyurea decreases the intracellular concentrations or deoxyadenosine triphosphate, the active metabolite of adenosine. We therefore tested the hypothesis that hydroxyurea could enhance the anti-HIV activity of low-dose tenofovir in vivo. Eight patients received tenofovir DF, 75 mg, plus hydroxyurea, 500 mg bid, for 28 days. Changes in plasma HIV RNA levels were compared with a previously studied cohort of patients treated with tenofovir DF, 75 mg once daily (n = 8), or tenofovir placebo (n= 12). The median change in HIV RNA levels after 28 days of continuous treatment was -0.01 log(10) copies/ml for tenofovir placebo, -0.33 log(10) copies/ml for tenofovir 75 mg once daily, and -0.22 log(10) copies RNA/ml for tenofovir plus hydroxyurea. The difference between placebo and tenofovir-treated groups was significant (p < .05); however, the difference between thetenofovir and tenofovir plus hydroxyurea groups was not significant (p = .90). We conclude that hydroxyurea does not significantly enhance the antiviral activity of low-dose tenofovir.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 10:27:49